Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUnity Health Toronto

About this trial

Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon/GI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - whereby genetic testing is initiated and mediated by oncologists without traditional pre-test genetic counseling (GC) often using some form of paper-based patient pamphlets or videos. There is no standard, evidence-based approach to mainstreaming, leading to significant practice variation, a lack of coordinated care and ultimately, negative psychological impacts on patients. Digital solutions can address these gaps by providing a standardized, coordinated and patient-centered approach to deliver cancer genetic education. However, digital solutions for providing cancer genetics services are uncommon and clinical-effectiveness and service delivery outcomes have not been well-assessed. This study will test a digital mainstreaming platform called the Genetics Adviser for Mainstream care to assess its effectiveness in improving psychological outcomes and patient-centred care for mainstream cancer patients compared to standard of care.

Eligibility criteria

Qualifiers

Receiving germline testing related to primary cancer condition initiated by oncologist

18 years old or older.

Speak and read English

Disqualifiers

Receiving cancer genetic testing via a referral to a genetics clinic

Do not speak or read English

Under 18 years of age

Determined to have diminished, marginal and or fluctuating decisional capacity

Trial design

Treatments tested in this trial

  • Genetics Adviser for Mainstream Care (GA-Mainstream)
  • Mainstreaming Standard of Care

Treatment groups

180 Participants
are divided into 2 treatment groups

Sponsors and collaborators